Baudax Bio, Inc. BXRXQ
—
0.00
0.00
NaN
as of 25 Sep
- Market cap
- —
- P/E
- 0.0×
Follow BXRXQ
Growth Flags
show if company had growth for consecutive years
| Dec '19 | Dec '20 | Dec '21 | Dec '22 | |
|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | 0.00 | 15.63 | 1.06 |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | (1.29) | (1.33) | (0.08) |
P/B ratio |
— | 0.00 | 1.28 | 0.00 |
Price to Tangible BV |
— | 0.00 | 0.00 | 0.00 |
EV/Sales |
— | 0.00 | 8.81 | 2.79 |
EV/EBITDA |
— | 0.03 | 0.00 | 0.00 |
EV/Operating CF |
— | 0.05 | (0.19) | (0.11) |
EV/FCF |
— | 0.05 | (0.19) | (0.11) |
Quick Ratio |
2.30 | 1.68 | 1.05 | 0.26 |
Current Ratio |
2.61 | 2.03 | 1.50 | 0.30 |
Net Debt/EBITDA |
0.55 | 0.29 | 0.45 | (0.03) |
Debt/Assets |
0.00% | 13.32% | 16.01% | 70.96% |
Debt/Equity |
0.00 | (0.62) | 0.65 | (0.29) |
Asset Turnover |
— | 0.01 | 0.02 | 0.04 |
Operating CF/Net income |
1.54 | 0.58 | 2.49 | 0.47 |
Capex/Depreciation |
(2.75) | (0.25) | (0.07) | (0.01) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 |
| 0.00% | 482.87% | 2,513.54% | 1,067.45% | |
| 0.00% | (123.79%) | (32.41%) | (185.74%) | |
ROIC |
0.00% | 0.00% | (202.50%) | 0.00% |
Return on Tangible Assets |
(188.81%) | (321.91%) | (153.69%) | 408.04% |
Average Days of Receivables |
— | 37.76 | 183.18 | 96.36 |
Research and Development Expense of Revenue |
0.00% | 1,843.20% | 289.35% | 306.30% |
Selling, General and Administrative Expense of Revenue |
0.00% | 8,790.06% | 4,195.37% | 1,900.63% |
Intangible Assets out of Total Assets |
0.53 | 0.38 | 0.45 | 0.21 |
Share Based Compensation of Revenue |
0.00% | 1,894.73% | 443.43% | 110.40% |
Graham Net Nets |
— | (2.49) | (0.98) | (24.31) |
Graham Number |
— | 11,951.18 | 0.00 | 678.16 |
Earnings Yield |
— | (403.46%) | (159.89%) | (8,090.46%) |
Free Cash Flow Yield |
— | (244.68%) | (293.11%) | (2,432.53%) |
Revenue per Share |
0.00 | 37.07 | 19.64 | 3.82 |
Operating CF per Share |
(7,469.25) | (3,312.63) | (895.82) | (83.71) |
Capex per Share |
(196.87) | (48.05) | (3.69) | (0.06) |
Free Cash Flow per Share |
(7,666.12) | (3,360.68) | (899.51) | (83.77) |
Cash per Share |
2,647.76 | 2,281.35 | 288.93 | 15.84 |
Shareholders Equity per Share |
(2,495.67) | (1,112.71) | 240.47 | (73.02) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(2,495.67) | (1,112.71) | 240.47 | (73.02) |
Free Cash Flow |
(51.36) | (44.70) | (49.47) | (27.81) |
Working Capital |
12.42 | 18.59 | 7.85 | (15.11) |
Capital Expenditures |
(1.32) | (0.64) | (0.20) | (0.02) |
Net Current Asset Value |
(50.80) | (46.81) | (16.56) | (27.93) |
EV/EBIT |
— | 0.03 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 1.30 | 0.19 | 0.02 |
Net Profit Margin |
0.00% | (15,436.11%) | (1,830.46%) | (4,633.18%) |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 |
| Other line items | ||||
Depreciation/Fixed assets |
0.10 | 0.51 | 0.56 | 3.07 |
Cash ROIC |
(5,384.20%) | (198.87%) | (144.19%) | 240.20% |
Accounts Receivable Turnover |
— | 0.00 | 3.64 | 2.89 |
Accounts Payable Turnover |
— | 0.88 | 0.95 | 2.60 |
Inventory Turnover |
— | 0.00 | 0.61 | 0.00 |
Average Days of Payables |
0.00 | 769.83 | 219.15 | 204.50 |
Days of Inventory on Hand |
— | 627.58 | 746.72 | 0.00 |
Average Receivables |
— | — | 0.30 | 0.44 |
Average Payables |
— | 1.96 | 2.56 | 2.70 |
Average Inventory |
— | — | 3.99 | — |
Average Assets |
— | 61.47 | 61.01 | 31.65 |
Average Common Equity |
— | (15.76) | (0.79) | (5.51) |
Columns are period end dates